Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1966 1
1967 1
1968 1
1969 2
1970 1
1971 2
1972 4
1973 3
1974 2
1975 32
1976 30
1977 27
1978 33
1979 31
1980 29
1981 51
1982 42
1983 57
1984 50
1985 90
1986 91
1987 90
1988 98
1989 87
1990 89
1991 96
1992 109
1993 132
1994 102
1995 98
1996 118
1997 110
1998 115
1999 104
2000 106
2001 116
2002 157
2003 191
2004 163
2005 135
2006 150
2007 182
2008 204
2009 244
2010 246
2011 308
2012 250
2013 285
2014 293
2015 269
2016 282
2017 275
2018 245
2019 247
2020 268
2021 267
2022 243
2023 260
2024 102

Text availability

Article attribute

Article type

Publication date

Search Results

6,775 results

Results by year

Filters applied: . Clear all
Page 1
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM. Hochhaus A, et al. Leukemia. 2016 May;30(5):1044-54. doi: 10.1038/leu.2016.5. Epub 2016 Feb 3. Leukemia. 2016. PMID: 26837842 Free PMC article. Clinical Trial.
In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a lower risk of progression to accelerated phase/blast crisis (AP/BC) than imatinib in pa …
In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, nilotinib result …
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial.
Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. Cortes JE, et al. J Clin Oncol. 2016 Jul 10;34(20):2333-40. doi: 10.1200/JCO.2015.64.8899. Epub 2016 May 23. J Clin Oncol. 2016. PMID: 27217448 Free PMC article. Clinical Trial.
PURPOSE: We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term efficacy and safety outcomes of patients with chronic myeloi …
PURPOSE: We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloi …
Management of advanced-phase chronic myeloid leukemia.
DeFilipp Z, Khoury HJ. DeFilipp Z, et al. Curr Hematol Malig Rep. 2015 Jun;10(2):173-81. doi: 10.1007/s11899-015-0249-2. Curr Hematol Malig Rep. 2015. PMID: 25929768 Review.
The management of chronic myeloid leukemia (CML) in accelerated or blast phase (advanced phase) remains a significant challenge despite the introduction of very effective tyrosine kinase inhibitors (TKIs). The biology of advanced-phase CM …
The management of chronic myeloid leukemia (CML) in accelerated or blast phase (advanced phase) remains a …
Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?
Patel AB, Wilds BW, Deininger MW. Patel AB, et al. Expert Rev Hematol. 2017 Jul;10(7):659-674. doi: 10.1080/17474086.2017.1330144. Epub 2017 May 22. Expert Rev Hematol. 2017. PMID: 28511567 Review.
With the discovery of imatinib mesylate nearly 20 years ago, tyrosine kinase inhibitors (TKIs) were found to be effective in chronic myeloid leukemia (CML). TKI therapy has since revolutionized the treatment of CML and has served as a paradigm of success for …
With the discovery of imatinib mesylate nearly 20 years ago, tyrosine kinase inhibitors (TKIs) were found to be effective in chronic …
Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
Haddad FG, Issa GC, Jabbour E, Yilmaz M. Haddad FG, et al. Expert Opin Pharmacother. 2022 May;23(7):751-758. doi: 10.1080/14656566.2022.2064742. Epub 2022 Apr 12. Expert Opin Pharmacother. 2022. PMID: 35412404 Review.
INTRODUCTION: Patients with chronic myeloid leukemia in chronic phase (CP-CML) who are resistant or intolerant to second-generation tyrosine kinase inhibitors (TKIs) may benefit from treatment with a third-generation TKI, like ponatinib. ...
INTRODUCTION: Patients with chronic myeloid leukemia in chronic phase (CP-CML) who are resistant or intol …
What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia?
Harrington P, Radia D, de Lavallade H. Harrington P, et al. Expert Rev Hematol. 2020 Mar;13(3):213-222. doi: 10.1080/17474086.2020.1717944. Epub 2020 Jan 29. Expert Rev Hematol. 2020. PMID: 31952452 Review.
Introduction: The outlook for patients with chronic myeloid leukemia (CML) has changed dramatically with the development of tyrosine kinase inhibitors (TKIs) with the current treatment goal for many patients being to obtain a durable deep molecular remission, …
Introduction: The outlook for patients with chronic myeloid leukemia (CML) has changed dramatically with the developmen …
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia.
Huguet F, Réa D, Cayssials E, Etienne G, Nicolini FE. Huguet F, et al. Expert Rev Hematol. 2023 Jul-Dec;16(9):633-639. doi: 10.1080/17474086.2023.2234084. Epub 2023 Jul 27. Expert Rev Hematol. 2023. PMID: 37427999 Clinical Trial.
AREAS COVERED: Based on pharmacological findings and international guidelines on chronic myeloid leukemia and cardiovascular risk management, as well as on the most recent data collected in real-life studies and in a randomized phase II trial, we propo …
AREAS COVERED: Based on pharmacological findings and international guidelines on chronic myeloid leukemia and cardiovas …
The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment.
Jain N, O'Brien S. Jain N, et al. Expert Rev Hematol. 2013 Oct;6(5):575-86. doi: 10.1586/17474086.2013.835697. Epub 2013 Oct 2. Expert Rev Hematol. 2013. PMID: 24083594 Review.
The use of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of chronic myeloid leukemia (CML). For patient with chronic phase CML, frontline treatment with imatinib leads to an estimated event-free survival and overall survival …
The use of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of chronic myeloid leukemia (CML). For pa …
6,775 results